Literature DB >> 9653047

Chemokine receptors in HIV-1 infection of the central nervous system.

D Gabuzda1, J He, A Ohagen, A V Vallat.   

Abstract

Several members of the chemokine receptor are used as coreceptors for HIV-1 infection in the central nervous system (CNS). CCR5 and CCR3 are coreceptors together with CD4 for HIV-1 infection of microglia, the major target for HIV-1 infection in the CNS. Microglia express CXCR4, but their infection by HIV-1 viruses that use only CXCR4 as a coreceptor is relatively inefficient. CXCR4 is also expressed in subpopulations of neurons that are resistant to HIV-1 infection. Additional orphan chemokine receptors that can mediate HIV-1 or SIV entry are expressed in the brain or neurally-derived cell lines, but their role in CNS infection has not been defined. The pattern of chemokine receptor expression in the brain is likely to determine the tropism of HIV-1 for particular CNS target cells and to impact inflammatory and degenerative mechanisms associated with CNS infection. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9653047     DOI: 10.1006/smim.1998.0133

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  29 in total

Review 1.  Chemokine receptors and neural function.

Authors:  Charlene Cho; Richard J Miller
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

Review 2.  Lentiviral neuropathogenesis: comparative neuroinvasion, neurotropism, neurovirulence, and host neurosusceptibility.

Authors:  Megan K Patrick; James B Johnston; Christopher Power
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

3.  Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 disease.

Authors:  B Schramm; M L Penn; R F Speck; S Y Chan; E De Clercq; D Schols; R I Connor; M A Goldsmith
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production through IL-1beta.

Authors:  Hui Peng; Nathan Erdmann; Nicholas Whitney; Huangyu Dou; Santhi Gorantla; Howard E Gendelman; Anuja Ghorpade; Jialin Zheng
Journal:  Glia       Date:  2006-11-01       Impact factor: 7.452

Review 5.  Role of microglia in central nervous system infections.

Authors:  R Bryan Rock; Genya Gekker; Shuxian Hu; Wen S Sheng; Maxim Cheeran; James R Lokensgard; Phillip K Peterson
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS.

Authors:  Eliseo A Eugenin; Kristin Osiecki; Lillie Lopez; Harris Goldstein; Tina M Calderon; Joan W Berman
Journal:  J Neurosci       Date:  2006-01-25       Impact factor: 6.167

Review 7.  Fractalkine (CX3CL1) and brain inflammation: Implications for HIV-1-associated dementia.

Authors:  R Cotter; C Williams; L Ryan; David Erichsen; A Lopez; H Peng; J Zheng
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

8.  HIV-1-infected and/or immune-activated macrophage-secreted TNF-alpha affects human fetal cortical neural progenitor cell proliferation and differentiation.

Authors:  Hui Peng; Nicholas Whitney; Yumei Wu; Changhai Tian; Huanyu Dou; You Zhou; Jialin Zheng
Journal:  Glia       Date:  2008-06       Impact factor: 7.452

9.  HIV-1-infected astrocytes and the microglial proteome.

Authors:  Tong Wang; Nan Gong; Jianuo Liu; Irena Kadiu; Stephanie D Kraft-Terry; Joshua D Schlautman; Pawel Ciborowski; David J Volsky; Howard E Gendelman
Journal:  J Neuroimmune Pharmacol       Date:  2008-06-28       Impact factor: 4.147

10.  Apoptosis induced by infection of primary brain cultures with diverse human immunodeficiency virus type 1 isolates: evidence for a role of the envelope.

Authors:  A Ohagen; S Ghosh; J He; K Huang; Y Chen; M Yuan; R Osathanondh; S Gartner; B Shi; G Shaw; D Gabuzda
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.